Kyongbo Pharmaceutical경보제약
214390 · KOSPI · ₩214390 · 경보제약
₩5,190▲ ₩20 (0.39%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩264B | ₩239B | ₩216B | ₩196B | ₩171B |
| Cost of sales | ₩162B | ₩156B | ₩153B | ₩152B | ₩135B |
| Gross profit | ₩102B | ₩82B | ₩63B | ₩44B | ₩35B |
| Operating income | ₩3.5B | ₩10B | ₩5.5B | ₩1.4B | −₩6.6B |
| Net income | ₩182M | ₩4.6B | ₩3B | ₩611M | −₩7.5B |
| Net income to shareholders | ₩182M | ₩4.6B | ₩3B | ₩611M | −₩7.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩320B | ₩284B | ₩266B | ₩241B | ₩237B |
| Current assets | ₩159B | ₩152B | ₩136B | ₩116B | ₩111B |
| Cash and equivalents | ₩7.2B | ₩4.1B | ₩4.5B | ₩6.3B | ₩4.3B |
| Total liabilities | ₩174B | ₩138B | ₩122B | ₩97B | ₩91B |
| Current liabilities | ₩147B | ₩133B | ₩118B | ₩96B | ₩89B |
| Borrowings | ₩125B | ₩89B | ₩73B | ₩64B | ₩56B |
| Total equity | ₩146B | ₩146B | ₩144B | ₩144B | ₩146B |
| Shareholders' equity | ₩146B | ₩146B | ₩144B | ₩144B | ₩146B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩7.5B | ₩149M | ₩4.8B | ₩10B | ₩18B |
| Capital spending | ₩42B | ₩13B | ₩9.7B | ₩13B | ₩18B |
| Free cash flow | −₩34B | −₩13B | −₩4.8B | −₩2.7B | ₩462M |
| Dividends paid | ₩1.2B | ₩1.2B | ₩1.2B | ₩1.2B | ₩2.4B |
Consolidated where available. Amounts in won.
Also known as: Kyongbo Pharmaceutical / 경보제약 / 214390 / KRX:214390
Source: KRX statistical information